Related Experiment Video
Updated: Aug 11, 2026
Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
Published on: August 14, 2012
The antitumor activity of the somatostatin structural derivative (TT-232) on different human tumor xenografts
1National Institute of Oncology, Department of Experimental Pharmacology, 1122 Rath Gy. u. 7-9, Budapest, Hungary. mtejeda.farm@oncol.hu
Abstract:
A somatostatin structural derivative (TT-232) has been developed in our laboratory with strong antiproliferative effect but no GH- release inhibitory activity. TT-232 inhibited tyrosine kinase activity of tumor cells lines and this inhibition correlated well with the inhibition of cell proliferation. The antineoplastic activity of TT-232 has been found to be associated with induction of programmed cell death (apoptosis) in tumor cell, resulting in highly selective elimination of neoplastic tissue. The aim of this study was the therapeutic efficacy of TT-232 on different human models: PC-3 prostate carcinoma, MDA-MB-231 (ER-) and MCF-7 (ER+) breast carcinoma, HT-29 colon carcinoma, HT-18 melanoma, HL-60 promyelocytic leukemia. We studied the therapeutic efficacy of the novel somatostatin analog, it for 30 days with intermittent injection once daily and for 14 days with s.c. infusion using the Alzet osmotic minipump (model 2002). The antitumor activity of TT-232 was evaluated on the basis of survival time and tumor growth inhibition. The tumor growth inhibitory effect of TT-232 on human tumor xenografts proved to be significant, resulting in 30%-80% decrease in tumor volume and in 20-60% tumor free animals. This antitumor efficacy of the novel somatostatin analog was observable in almost all tumors investigated. These data suggest that the novel somatostatin analog (TT-232) is an effective and promising antitumor agent.
Insights
A novel somatostatin analog, TT-232, effectively inhibits tumor cell proliferation and induces apoptosis. This promising antitumor agent demonstrated significant efficacy across various human cancer models, offering a new therapeutic avenue.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- A novel somatostatin structural derivative, TT-232, exhibits potent antiproliferative effects without inhibiting growth hormone (GH) release.
- TT-232 targets tyrosine kinase activity in tumor cells, correlating with inhibited cell proliferation.
- The antineoplastic activity of TT-232 is linked to the induction of programmed cell death (apoptosis) in tumor cells, leading to selective elimination of neoplastic tissue.
Purpose of the Study:
- To evaluate the therapeutic efficacy of TT-232 against a panel of human tumor xenografts.
- To assess the antitumor activity of TT-232 using different administration schedules and delivery methods.
Main Methods:
- TT-232 was administered to human tumor xenografts (PC-3 prostate, MDA-MB-231/MCF-7 breast, HT-29 colon, HT-18 melanoma, HL-60 leukemia) via daily intermittent injections for 30 days or subcutaneous infusion for 14 days using Alzet osmotic minipumps.
- Antitumor activity was quantified by monitoring survival time and tumor growth inhibition.
Main Results:
- TT-232 demonstrated significant antitumor activity across multiple human cancer models.
- Tumor volume decreased by 30%-80%, and 20%-60% of animals achieved tumor-free status.
- The efficacy of TT-232 was observed in nearly all investigated tumor types.
Conclusions:
- The novel somatostatin analog TT-232 is a highly effective and promising antitumor agent.
- TT-232 exhibits broad-spectrum anticancer activity through tyrosine kinase inhibition and apoptosis induction.
- These findings support the potential of TT-232 as a novel therapeutic strategy for various cancers.
